www.fdanews.com/articles/87256-advancis-pharmaceutical-completes-enrollment-in-amoxicillin-pulsys-phase-iii-trial
ADVANCIS PHARMACEUTICAL COMPLETES ENROLLMENT IN AMOXICILLIN PULSYS PHASE III TRIAL
June 1, 2006
Advancis Pharmaceutical Corporation (Nasdaq: AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has completed enrollment in the Company's Amoxicillin PULSYS Phase III clinical trial for the treatment of pharyngitis/tonsillitis due to Group A streptococcal infections. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-01-2006/0004372095&EDATE=)